Clinical Trial


Phase 2 study
Testing the safety and tolerability of Alogobat, administered as once-daily oral tablet.

Alogabat is a GABA-modulator which aims to restore GABA functioning which would improve symptoms and potentially aid brain development.


Participant Requirements

Below is a preliminary list of inclusion criteria.
See the full list of eligibility criteria on the clinical trials website.

  • Clinical diagnosis of deletion genotype of Angelman syndrome
  • Between 5 and 17 years old
  • Able to undergo blood draws, ECG and EEG assessments


Boston, MA
Boston Children’s Hospital

Chicago, IL
Rush Medical Center

New York, NY
Columbia University Medical Center

Carrboro, NC
Carolina Institute for Development Disabilities University of North Carolina/School of Medicine

Bedford Park, Australia, South Australia
Flinders Medical Centre Recruiting

Marseille, France
Hopital la Timone Enfants; Service de Pediatrie et Neurologie Pediatrique

Paris, France
Groupe Hospitalier Necker Enfants Malades

Roma, Lazio, Italy
Ospedale Pediatrico Bambino Gesù; Dip. Neuroscienze e Neuroriabilitazione

Genova, Liguria, Italy
IRCCS Istituto G. Gaslini; UOC Neurologia Pediatrica e Malattie Muscolari

Sabadell, Barcelona, Spain
Corporacio Sanitaria Parc Tauli

More Information and Screening Enrollment

Find more information on the Roche website.

More details on

Questions about this study and enrollment interest can be directed to:
888-662-6728 (US and Canada) or

Reference Study ID Number: BP41315